- Home
- DJCO vs ANAB Comparison
DJCO vs ANAB Comparison
Compare DJCO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DJCO
- ANAB
- Stock Information
- Founded
- DJCO 1987
- ANAB 2005
- Country
- DJCO United States
- ANAB United States
- Employees
- DJCO N/A
- ANAB N/A
- Industry
- DJCO Newspapers/Magazines
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- DJCO Consumer Discretionary
- ANAB Health Care
- Exchange
- DJCO Nasdaq
- ANAB Nasdaq
- Market Cap
- DJCO 569.1M
- ANAB 621.1M
- IPO Year
- DJCO N/A
- ANAB 2017
- Fundamental
- Price
- DJCO $395.06
- ANAB $27.06
- Analyst Decision
- DJCO
- ANAB Buy
- Analyst Count
- DJCO 0
- ANAB 10
- Target Price
- DJCO N/A
- ANAB $44.25
- AVG Volume (30 Days)
- DJCO 73.2K
- ANAB 515.5K
- Earning Date
- DJCO 08-13-2025
- ANAB 08-04-2025
- Dividend Yield
- DJCO N/A
- ANAB N/A
- EPS Growth
- DJCO 375.38
- ANAB N/A
- EPS
- DJCO 76.72
- ANAB N/A
- Revenue
- DJCO $73,247,000.00
- ANAB $111,872,000.00
- Revenue This Year
- DJCO N/A
- ANAB N/A
- Revenue Next Year
- DJCO N/A
- ANAB $24.39
- P/E Ratio
- DJCO $5.08
- ANAB N/A
- Revenue Growth
- DJCO 1.99
- ANAB 387.20
- 52 Week Low
- DJCO $359.34
- ANAB $12.21
- 52 Week High
- DJCO $602.00
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- DJCO 43.44
- ANAB 70.24
- Support Level
- DJCO $385.91
- ANAB $23.10
- Resistance Level
- DJCO $443.50
- ANAB $26.17
- Average True Range (ATR)
- DJCO 13.57
- ANAB 1.33
- MACD
- DJCO -3.32
- ANAB 0.27
- Stochastic Oscillator
- DJCO 15.89
- ANAB 100.00
About DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).